EUVIMEDEUVIMED entdecken
Crossref

Outcomes of Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: How Do Anti‐HLA Antibodies Impact?

Gizem Zengin Ersoy iD, Basak Adakli Aksoy iD, Melek Erdem, Lokman Karataş, Selime Aydoğdu, Özlem Başoğlu Öner, Gürcan Dikme, Ceyhun Bozkurt, Tunç Fışgın

Clinical Transplantation · 2024

DOI: 10.1111/ctr.70035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, 2024. Verfasst von Gizem Zengin Ersoy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Medical Park Bahçelievler Hospital, Department of Pediatric Hematology Oncology & Pediatric Bone Marrow Transplantation Unit, Al…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, beta-Thalassemia, Graft vs Host Disease, HLA Antigens. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate the effects of anti‐human Leucocyte Antigen (HLA) antibody positivity on early hematopoietic stem cell transplantation (HSCT) results in patients with thalassemia major (TM).

Methods

One hundred and twenty‐four HLA‐matched HSCTs were performed in patients with TM between 2015 and 2022. Ninety‐one patients were screened for anti‐HLA antibodies by testing panel reactive antigens (PRA). Demographic and transplantation characteristics of patients were recorded. The presence of PRA was tested with the Antibody Testing Assay (Luminex LIFECODES HLA Antibody Identification System).

Results

The number of PRA‐positive patients was 54. There was no relationship between acute graft versus host disease (GVHD), chronic GVHD, grade of GVHD, and viral reactivation of the patients. However, platelet engraftment took around 3 days longer in the PRA‐positive group ( p = 0.05). The median number of erythrocyte transfusions was significantly higher in PRA‐positive patients in the post‐transplant period ( p = 0.003), as was the median number of platelet transfusions ( p = 0.003). Treosulfan conditioning increased the stable mixed chimerism (MC) rate by 3.8‐fold ( p = 0.011). In contrast, reduced rates of MC were found in patients who received matched unrelated donor cells or peripherally derived stem cells ( p = 0.011 and p = 0.039, respectively) in the posttransplantation period in TM patients. PRA‐positivity did not affect MC ( p = 0.478). However, 80% of patients who had primary graft failure ( n = 5; p = 0.59) and 75% of patients who died ( n = 4) were PRA positive ( p = 0.64), but these results were statistically insignificant due to the low number of patients.

Conclusion

Anti‐HLA antibodies primarily delayed platelet engraftment in TM patients and increased the erythrocyte and thrombocyte transfusion requirements. Although PRA positivity was more common in patients with primary graft failure or who died, there was no statistically significant impact of PRA positivity on chimerism, acute or chronic GVHD, viral activation, or mortality rates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell Transplantationbeta-ThalassemiaGraft vs Host DiseaseHLA AntigensIsoantibodiesHumansMaleFemaleChildFollow-Up StudiesPrognosisAdolescentChild, PreschoolYoung AdultAdultTransplantation ConditioningGraft SurvivalRetrospective StudiesSurvival RateRisk Factors

Stichwörter der Autor:innen

anti‐HLA antibodiespanel reactive antigensthalassemia majortransplantation

Substanzen

HLA AntigensIsoantibodies

Autor:innen und Institutionen

  • Faculty of Medicine, Medical Park Bahçelievler Hospital, Department of Pediatric Hematology Oncology & Pediatric Bone Marrow Transplantation Unit, Altınbaş University, Istanbul, Turkey.
  • Faculty of Medicine, Medical Park Bahçelievler Hospital, Department of Pediatric Hematology Oncology & Pediatric Bone Marrow Transplantation Unit, Istinye University, Istanbul, Turkey.
  • Istinye University, Department of Immunology, Laboratory of Immunology and HLA Analysis, Istanbul, Turkey.
  • Umraniye Research & Training Hospital, Department of Pediatric Hematology & Oncology, Medical Sciences University, Istanbul, Turkey.
  • Aydin University Pediatric Hematology & Oncology, Istanbul, Turkey.

ORCID-Profile: Gizem Zengin Ersoy, Basak Adakli Aksoy

Zitieren

APA

Ersoy, G. Z., Aksoy, B. A., Erdem, M., Karataş, L., Aydoğdu, S., Öner, Ö. B., Dikme, G., Bozkurt, C., & Fışgın, T. (2024). Outcomes of Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: How Do Anti‐HLA Antibodies Impact?. Clinical Transplantation. https://doi.org/10.1111/ctr.70035

Vancouver

Ersoy GZ, Aksoy BA, Erdem M, Karataş L, Aydoğdu S, Öner ÖB, et al. Outcomes of Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: How Do Anti‐HLA Antibodies Impact?. Clinical Transplantation. 2024. doi:10.1111/ctr.70035

BibTeX
@article{Ersoy2024,
  author = {Ersoy, Gizem Zengin and Aksoy, Basak Adakli and Erdem, Melek and Karataş, Lokman and Aydoğdu, Selime and Öner, Özlem Başoğlu and Dikme, Gürcan and Bozkurt, Ceyhun and Fışgın, Tunç},
  title = {Outcomes of Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: How Do Anti‐HLA Antibodies Impact?},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.70035}
}
Kostenlos starten →